Researchers reported systemic delivery of full-length DMD mRNA using skeletal-muscle-targeted extracellular vesicles in a murine Duchenne model. The study, published in Nature Biomedical Engineering, describes engineered targeting EVs (DMD t-EVs) designed to deliver full-length dystrophin coding material after injection into the bloodstream. The preclinical work reported restored dystrophin production alongside improvements in muscle strength and function. The authors also reported safety and biocompatibility findings in non-human primates, aiming to address viral-vector size constraints that limit current approaches for DMD’s unusually large gene.